UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

The New England journal of medicine, 2017-11, Vol.377 (20), p.1930-1942

2017

Link zum Volltext

Verfügbarkeit prüfen

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

Clinical journal of the American Society of Nephrology, 2016-05, Vol.11 (5), p.803-811

2016

Link zum Volltext

Verfügbarkeit prüfen

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

Kidney international, 2019-07, Vol.96 (1), p.159-169

2019

Link zum Volltext

Verfügbarkeit prüfen

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

Journal of the American Society of Nephrology, 2017-05, Vol.28 (5), p.1592-1602

2017

Link zum Volltext

Verfügbarkeit prüfen

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys

Journal of digital imaging, 2017-08, Vol.30 (4), p.442-448

2017

Link zum Volltext

Verfügbarkeit prüfen

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

American journal of kidney diseases, 2017-02, Vol.69 (2), p.210-219

2017

Link zum Volltext

Verfügbarkeit prüfen

Perk-Dependent Translational Regulation Promotes Tumor Cell Adaptation and Angiogenesis in Response to Hypoxic Stress

Molecular and Cellular Biology, 2006-12, Vol.26 (24), p.9517-9532

2006

Link zum Volltext

Verfügbarkeit prüfen

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

Nephrology, dialysis, transplantation, 2018-04, Vol.33 (4), p.645-652

2018

Link zum Volltext

Verfügbarkeit prüfen

Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic Stress

Molecular and Cellular Biology, 2004-09, Vol.24 (17), p.7469-7482

2004

Link zum Volltext

Verfügbarkeit prüfen

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Kidney international reports, 2017-11, Vol.2 (6), p.1132-1140

2017

Link zum Volltext

Verfügbarkeit prüfen

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Nephrology, dialysis, transplantation, 2017-08, Vol.32 (8), p.1356-1363

2017

Link zum Volltext

Verfügbarkeit prüfen

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials

Cancer medicine (Malden, MA), 2017-04, Vol.6 (4), p.723-729

2017

Link zum Volltext

Verfügbarkeit prüfen

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Nephrology, dialysis, transplantation, 2018-03, Vol.33 (3), p.477-489

2018

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial

Kidney international reports, 2016-11, Vol.1 (4), p.213-220

2016

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug safety, 2015-11, Vol.38 (11), p.1103-1113

2015

Link zum Volltext

Verfügbarkeit prüfen

Resistance to Vesicular Stomatitis Virus Infection Requires a Functional Cross Talk between the Eukaryotic Translation Initiation Factor 2α Kinases PERK and PKR

Journal of Virology, 2004-12, Vol.78 (23), p.12747-12761

2004

Link zum Volltext

Verfügbarkeit prüfen

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Nephrology, dialysis, transplantation, 2017-07, Vol.32 (7), p.1262-1262

2017

Link zum Volltext

Verfügbarkeit prüfen

Internal Ribosome Entry Site-mediated Translation of Apaf-1, but Not XIAP, Is Regulated during UV-induced Cell Death

The Journal of biological chemistry, 2006-06, Vol.281 (22), p.15155-15163

2006

Link zum Volltext

Verfügbarkeit prüfen

A Small Molecule Inhibitor of Endoplasmic Reticulum Oxidation 1 (ERO1) with Selectively Reversible Thiol Reactivity

The Journal of biological chemistry, 2010-07, Vol.285 (27), p.20993-21003

2010

Link zum Volltext

Verfügbarkeit prüfen

Internal Translation Initiation Mediated by the Angiogenic Factor Tie2

The Journal of biological chemistry, 2005-06, Vol.280 (22), p.20945-20953

2005

Link zum Volltext

Verfügbarkeit prüfen

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

Clinical kidney journal, 2019-02, Vol.12 (1), p.71-77

2019

Link zum Volltext

Verfügbarkeit prüfen

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Metabolism, clinical and experimental, 2021-03, Vol.116, p.154509, Article 154509

2021

Link zum Volltext

Verfügbarkeit prüfen

Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR

Journal of virology, 2004-12, Vol.78 (23), p.12747-12761

2004

Link zum Volltext

Verfügbarkeit prüfen

Regulation of translation during hypoxic stress: An integrated stress response

Blais, Jaime D

2006

Link zum Volltext

Verfügbarkeit prüfen

ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth

The EMBO journal, 2005-10, Vol.24 (19), p.3470-3481

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(44)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(24)
Humans
(16)
Physical Sciences
(16)
Chemistry
(15)
Urology & Nephrology
(13)
Chemistry, Multidisciplinary
(12)
Nephrology
(10)
Tolvaptan
(9)
Female
(8)
Male
(8)
Adult
(7)
Autosomal Dominant Polycystic Kidney Disease
(7)
Dendrimers
(7)
Middle Aged
(7)
Transplantation
(7)
Animals
(6)
Antidiuretic Hormone Receptor Antagonists - Therapeutic Use
(6)
Benzazepines - Therapeutic Use
(6)
Biochemistry & Molecular Biology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial

Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial

Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys

Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial

Perk-Dependent Translational Regulation Promotes Tumor Cell Adaptation and Angiogenesis in Response to Hypoxic Stress

Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial

Activating Transcription Factor 4 Is Translationally Regulated by Hypoxic Stress

Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4

Prevalence of autosomal dominant polycystic kidney disease in the European Union

Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT‐1 and SALT‐2 trials

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Resistance to Vesicular Stomatitis Virus Infection Requires a Functional Cross Talk between the Eukaryotic Translation Initiation Factor 2α Kinases PERK and PKR

Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Internal Ribosome Entry Site-mediated Translation of Apaf-1, but Not XIAP, Is Regulated during UV-induced Cell Death

A Small Molecule Inhibitor of Endoplasmic Reticulum Oxidation 1 (ERO1) with Selectively Reversible Thiol Reactivity

Internal Translation Initiation Mediated by the Angiogenic Factor Tie2

Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR

Regulation of translation during hypoxic stress: An integrated stress response

ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth

Suchergebnisse filtern